MINI LONG - VICE PHAR Share Price

MINI L VICO AVA

GB00BQRBMS95

Delayed Nasdaq Stockholm 07:03:58 31/05/2024 pm IST
11.75 ^SEK	+44.00%

3 months	+261.54%
6 months	+111.71%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VICORE PHARMA HOLDING AB

Latest news about VICORE PHARMA HOLDING AB

Increase of number of shares and votes in Vicore Pharma	31/05	AQ
Transcript : Vicore Pharma Holding AB - Special Call	22/05
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis	20/05	AQ
Vicore Pharma Holding AB Announces Positive Final Results from the Phase 2a Air Trial Demonstrating Buloxibutid Improves Lung Function over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis	20/05	CI

More news

Quotes 5-day view

Date	Price	Change
31/24/31	11.75	+44.00%
29/24/29	8.16	+11.17%
28/24/28	7.34	+23.15%

Delayed Quote Nasdaq Stockholm

Last update May 31, 2024 at 07:03 pm IST

More quotes

Static data

Product type	Knock-Out with Stop Loss
Buy / Sell	CALL
Underlying	VICORE PHARMA HOLDING AB
Issuer	Morgan Stanley
	MINI L VICO AVA
ISIN	GB00BQRBMS95
Date issued	02/03/2023
Strike	9.908 kr
Maturity	Unlimited
Parity	1 : 1
Emission price	- kr
Emission volume	N/A
Settlement	cash
Currency	SEK

Technical Indicators

Highest since issue	16.03 kr
Lowest since issue	3.25 kr
Spread	-0.83 kr
Spread %	8.30%

Company Profile

Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.

Sector

More about the company

Consensus: Vicore Pharma Holding AB

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22 SEK

Average target price

61.5 SEK

Spread / Average Target

+179.55%

Consensus